Last reviewed · How we verify
Iron preparation
At a glance
| Generic name | Iron preparation |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Hemochromatosis (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis (PHASE2)
- Adherence to Oral Therapies in Advanced Breast and Prostate Cancers (NA)
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. (PHASE1)
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Mechanisms Accounting for Unexplained Anemia in the Elderly (PHASE1)
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron preparation CI brief — competitive landscape report
- Iron preparation updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI